These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 20876838

  • 21. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q, Rajagopalan S, Mavros P, Engel SS, Davies MJ, Yin D, Radican L.
    Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
    [Abstract] [Full Text] [Related]

  • 22. Diabetes under control: Understanding oral antidiabetic agents.
    Longo R.
    Am J Nurs; 2010 Feb; 110(2):49-52. PubMed ID: 20107402
    [No Abstract] [Full Text] [Related]

  • 23. Potential role of oral DPP-4 inhibitors in the ADA/EASD consensus statement algorithm for achieving and maintaining tight glycaemic control in type 2 diabetes: recommendations for oral antidiabetic agents.
    Barnett A.
    Int J Clin Pract Suppl; 2007 Aug; (154):12-8. PubMed ID: 17593273
    [Abstract] [Full Text] [Related]

  • 24. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus.
    Blonde L.
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S4-11. PubMed ID: 19952303
    [Abstract] [Full Text] [Related]

  • 25. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
    Bailey CJ, Green BD, Flatt PR.
    Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
    [Abstract] [Full Text] [Related]

  • 26. Defining the role of incretin mimetic therapy in the management of type 2 diabetes.
    Unger J, Nadeau DA.
    J Fam Pract; 2007 Dec; 56(12 Suppl New):S4-S10. PubMed ID: 18664341
    [Abstract] [Full Text] [Related]

  • 27. DPP IV inhibitors: successes, failures and future prospects.
    Kshirsagar AD, Aggarwal AS, Harle UN, Deshpande AD.
    Diabetes Metab Syndr; 2011 Dec; 5(2):105-12. PubMed ID: 22813415
    [Abstract] [Full Text] [Related]

  • 28. Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination.
    Ono Y, Kamoshima H, Nakamura A, Nomoto H.
    Expert Opin Pharmacother; 2014 Sep; 15(13):1785-95. PubMed ID: 25046055
    [Abstract] [Full Text] [Related]

  • 29. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
    Grunberger G.
    Postgrad Med; 2013 May; 125(3):79-90. PubMed ID: 23748509
    [Abstract] [Full Text] [Related]

  • 30. Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.
    Zhao Y, Yang L, Zhou Z.
    J Diabetes; 2014 Jan; 6(1):21-9. PubMed ID: 23683065
    [Abstract] [Full Text] [Related]

  • 31. [The expectation for DPP-4 inhibitors on future treatment of type 2 diabetes mellitus].
    Kawamori R.
    Nihon Rinsho; 2011 Aug; 69(8):1515-9. PubMed ID: 21838055
    [Abstract] [Full Text] [Related]

  • 32. [Importance of daily glycemic variability in achieving glycemic targets in type 2 diabetes: role of DPP-4 inhibitors].
    Ampudia-Blasco FJ, Ceriello A.
    Med Clin (Barc); 2010 Sep; 135 Suppl 2():33-9. PubMed ID: 21420536
    [Abstract] [Full Text] [Related]

  • 33. Clinical decisions. Glycemic management in a patient with type 2 diabetes.
    Hirsch IB, Molitch ME.
    N Engl J Med; 2013 Oct 03; 369(14):1370-2. PubMed ID: 24088099
    [No Abstract] [Full Text] [Related]

  • 34. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
    Singh AK, Singh R.
    Expert Rev Clin Pharmacol; 2016 Oct 03; 9(2):229-40. PubMed ID: 26589238
    [Abstract] [Full Text] [Related]

  • 35. [Use of oral glucose-lowering agents in patients with renal impairment].
    Scheen AJ.
    Rev Med Suisse; 2012 Aug 29; 8(351):1614-20. PubMed ID: 22988715
    [Abstract] [Full Text] [Related]

  • 36. [Efficacy of DPP-4 inhibitor evaluated by CGM (continuous glucose monitoring)].
    Nishimura R.
    Nihon Rinsho; 2012 Nov 29; 70(11):2023-9. PubMed ID: 23214078
    [Abstract] [Full Text] [Related]

  • 37. Alogliptin benzoate for the treatment of type 2 diabetes.
    Seino Y, Yabe D.
    Expert Opin Pharmacother; 2014 Apr 29; 15(6):851-63. PubMed ID: 24646052
    [Abstract] [Full Text] [Related]

  • 38. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
    Maezaki H, Banno Y, Miyamoto Y, Moritoh Y, Asakawa T, Kataoka O, Takeuchi K, Suzuki N, Ikedo K, Kosaka T, Sasaki M, Tsubotani S, Tani A, Funami M, Yamamoto Y, Tawada M, Aertgeerts K, Yano J, Oi S.
    Bioorg Med Chem; 2011 Aug 01; 19(15):4482-98. PubMed ID: 21741847
    [Abstract] [Full Text] [Related]

  • 39. [Dipeptidyl peptidase-4 inhibitors in type 2 diabetic elderly patient].
    Doucet J, Bauduceau B, Blicklé JF.
    Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun 01; 9(2):157-62. PubMed ID: 21690023
    [Abstract] [Full Text] [Related]

  • 40. The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring.
    Yata Y, Hosojima M, Kabasawa H, Ishikawa T, Kaseda R, Iino N, Suzuki Y, Saito A, Narita I.
    Intern Med; 2017 Oct 01; 56(19):2555-2562. PubMed ID: 28883231
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.